Hcw biologics to showcase its novel second-generation immune checkpoint inhibitor identified as a potential gateway to a multi-billion dollar market

Company's pembrolizumab-based immune checkpoint inhibitor exhibited success  against solid tumors in ind-enabling studies by simultaneously activating immune cells and promoting their infiltration into solid tumors presentation at nova southeastern university  on september 12, 2025, in fort lauderdale, florida miramar, fla., aug. 25, 2025 (globe newswire) -- hcw biologics inc. (the “company” or “hcw biologics”), (nasdaq: hcwb), a u.s.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, announced today that its scientists have successfully developed second-generation, pembrolizumab-based immunotherapeutics against solid tumors, particularly for pancreatic and ovarian cancer, using its novel proprietary trbc product discovery and development platform technology.
HCWB Ratings Summary
HCWB Quant Ranking